Iodine I-131

RADIATION3 trials

Sponsors

National Cancer Institute (NCI), Academic and Community Cancer Research United, City of Hope Medical Center

Conditions

Metastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland CarcinomaStage IV Thyroid Gland Follicular Carcinoma AJCC v7Stage IV Thyroid Gland Papillary Carcinoma AJCC v7Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7

Phase 2

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Active, not recruitingNCT02152995

National Cancer Institute (NCI)Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma +9

Start: 2014-08-14End: 2027-02-05Updated: 2026-04-03

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

CompletedNCT02393690

Academic and Community Cancer Research UnitedMetastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma +8

Start: 2015-05-04End: 2023-12-31Updated: 2024-07-26

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

RecruitingNCT06440850

City of Hope Medical CenterThyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma

Start: 2024-07-15End: 2026-11-22Target: 21Updated: 2026-02-02

Related Papers

[<sup>18</sup>F]TFB PET/CT misses intense [<sup>124</sup>I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer.

2024-10-08

Phase 2 of trametinib plus radioiodine in <i>RAS-</i>mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446).

Journal of Clinical Oncology2022-06-019 citations